Gunderson Dettmer represented client Viking Global as it led the $103 million Series B financing of Mythic Therapeutics, a biotechnology product platform. The company’s platform develops a pipeline of antibody-drug conjugates (ADCs) designed to exhibit therapeutic index and efficacy. The new capital will be used to finance the lead program through first-in-human clinical studies in lung cancer and fund pipeline development.

In the announcement of the transaction, president and CEO of Mythic Therapeutics Dr. Alex Nichols, Ph.D. said, “We are thrilled to partner with this distinguished group of investors. This financing validates the FateConyrol approach and supports our efforts to achieve expanded use of Mythic’s ADCs within and across indications, translating to improved outcomes for patients with unmet medical needs.”

The Gunderson deal team was led by Greg Volkmar and included David Sharrow, Brian Russell, Tina Xu, Cassie Averbuch, Joseph Erdos, and Erica Davis.

Companies:
Viking Global
Mythic Therapeutics